Figure 1 | British Journal of Cancer

Figure 1

From: Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases

Figure 1

Schematic diagram outlining experimental procedure: 9 days after tail vein injection, animals were anaesthesied and randomised to one of five groups. Group 1 received an i.p. injection of PBS (1 ml), group 2 10 mg LPS (in 1 ml PBS), group 3 underwent laparotomy as described previously, group 4 received 0.3 mg kg−1 WXC-340 (in 1 ml PBS) 1 h before intraperitoneal injection of 10 mg ml−1 LPS and group 5 received 0.3 mg Kg−1 WXC-340 (in 1 ml PBS) 1 h before laparotomy. Subsequently groups 1–3 received subcutaneous PBS (1 ml) daily, whereas groups 4 and 5 received subcutaneous 0.3 mg kg−1 WXC-340 (in 1 ml PBS).

Back to article page